Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Stocrin, Sustiva; Belgium: Stocrin; Bulgaria: Stocrin; Czech Republic: Stocrin, Sustiva; Denmark: Stocrin; Estonia: Stocrin, Sustiva; Finland: Stocrin; France: Sustiva; Germany: Stocrin, Sustiva; Greece: Stocrin, Sustiva; Hungary: Stocrin, Sustiva; Ireland: Stocrin; Italy: Sustiva; Latvia: Stocrin; Lithuania: Stocrin, Sustiva; Netherlands: Stocrin, Sustiva; Poland: Stocrin, Sustiva; Portugal: Stocrin, Sustiva; Romania: Stocrin, Sustiva; Slovakia: Stocrin, Sustiva; Spain: Sustiva; Sweden: Stocrin, Sustiva; UK: Sustiva.

North America

USA: Sustiva.

Latin America

Argentina: Efavilea, Filginase, Stocrin, Sulfinav, Virorrever; Brazil: Stocrin; Mexico: Stocrin.


Japan: Stocrin.

Drug combinations

Efavirenz, Emtricitabine, and Tenofovir


Efavirenz: C~14~H~9~ClF~3~NO~2~. Mw: 315.67. (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. CAS-154598-52-4.

Pharmacologic Category

Antiretrovirals; Non-nucleoside Reverse Transcriptase Inhibitors. (ATC-Code: J05AG03).

Mechanism of action

A synthetic antiretroviral agent, it is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Blocks RNA-dependent and DNA-dependent DNA polymerase activities including HIV-1 replication.

Therapeutic use

Used in conjunction with other antiretroviral agents for treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults, adolescents, and pediatric patients 3 years of age or older.

Pregnancy and lactiation implications

May cause fetal harm. Teratogenicity demonstrated in animals. Birth defects (including neural tube defects) reported in humans. Efavirenz should not be used in pregnant women, especially during the 1^st^ trimester. Unknown whether it is distributed into human milk. HIV-infected women should not breast-feed while receiving efavirenz due to risk of HIV transmission and risk of adverse effects in the infant.

Unlabeled use


Hypersensitivity to efavirenz or any component of the formulation. Concomitant use with drugs highly dependent on CYP3A for metabolism (e.g. cisapride, ergot alkaloids, midazolam, pimozide, triazolam). Concomitant use with usual dosage of voriconazole.

Warnings and precautions

Serious adverse psychiatric symptoms (aggressive behavior, nonfatal suicide attempts, paranoid reactions, severe depression, suicidal ideation) reported rarely in clinical studies. Dizziness or insomnia reported frequently; abnormal dreams, hallucinations, or impaired concentration also reported. Seizures reported rarely (caution if used in history of seizures). CNS effects may be potentiated when used with other sedative drugs or ethanol. Patients may develop immune reconstitution syndrome. High potential for interactions with CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates. May cause fetal harm. Pregnancy should be avoided. Rash (maculopapular skin eruptions, blistering, moist desquamation, or ulceration, erythema multiforme, and Stevens-Johnson syndrome) reported frequently. Rash reported more frequently in children than in adults. Concomitant use of multiple efavirenz-containing preparations should be avoided. Increases in total serum cholesterol and triglycerides have occurred. Possible redistribution or accumulation of body fat. Use with caution in the elderly due to age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy. Use with caution in hepatic impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart